Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pieter L. J. Degraeuwe is active.

Publication


Featured researches published by Pieter L. J. Degraeuwe.


Annals of Surgery | 2010

Non-Invasive Markers for Early Diagnosis and Determination of the Severity of Necrotizing Enterocolitis

Geertje Thuijls; Joep P. M. Derikx; Kim van Wijck; Luc J. I. Zimmermann; Pieter L. J. Degraeuwe; Twan Mulder; David van der Zee; Hens A. A. Brouwers; B.H. Verhoeven; L.W. Ernest van Heurn; Boris W. Kramer; Wim A. Buurman; Erik Heineman

Objectives:To improve diagnosis of necrotizing enterocolitis (NEC) by noninvasive markers representing gut wall integrity loss (I-FABP and claudin-3) and gut wall inflammation (calprotectin). Furthermore, the usefulness of I-FABP to predict NEC severity and to screen for NEC was evaluated. Methods:Urinary I-FABP and claudin-3 concentrations and fecal calprotectin concentrations were measured in 35 consecutive neonates suspected of NEC at the moment of NEC suspicion. To investigate I-FABP as screening tool for NEC, daily urinary levels were determined in 6 neonates who developed NEC out of 226 neonates included before clinical suspicion of NEC. Results:Of 35 neonates suspected of NEC, 14 developed NEC. Median I-FABP, claudin-3, and calprotectin levels were significantly higher in neonates with NEC than in neonates with other diagnoses. Cutoff values for I-FABP (2.20 pg/nmol creatinine), claudin-3 (800.8 INT), and calprotectin (286.2 &mgr;g/g feces) showed clinically relevant positive likelihood ratios (LRs) of 9.30, 3.74, 12.29, and negative LRs of 0.08, 0.36, 0.15, respectively. At suspicion of NEC, median urinary I-FABP levels of neonates with intestinal necrosis necessitating surgery or causing death were significantly higher than urinary I-FABP levels in conservatively treated neonates.Of the 226 neonates included before clinical suspicion of NEC, 6 developed NEC. In 4 of these 6 neonates I-FABP levels were not above the cutoff level to diagnose NEC before clinical suspicion. Conclusions:Urinary I-FABP levels are not suitable as screening tool for NEC before clinical suspicion. However, urinary I-FABP and claudin-3 and fecal calprotectin are promising diagnostic markers for NEC. Furthermore, urinary I-FABP might also be used to predict disease severity.


Gut | 2007

Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis

J. P. M. Derikx; N. J. Evennett; Pieter L. J. Degraeuwe; Twan Mulder; A. A. van Bijnen; L. W. E. van Heurn; W.A. Buurman; Erik Heineman

Necrotising enterocolitis (NEC) is a severe gastrointestinal disease with a mortality of 20–40%, affecting predominantly premature neonates.1 In the early phase of the disease NEC continues to present a diagnostic challenge for the attending clinician. The signs and symptoms are often non-specific, including gastrointestinal problems such as abdominal distension and feeding intolerance, which are also among the most prevalent presenting features of neonatal sepsis.2 The diagnosis is further hampered by the limited diagnostic accuracy of the laboratory and radiological tests currently in use.3,4 Histopathologically, NEC is characterised by intestinal coagulative or ischaemic necrosis, starting at the mucosa and extending into the submucosa and muscularis externa.1 We sought a non-invasive test to find evidence of enterocyte cell death in infants with gastrointestinal symptoms suspicious of NEC, in order to differentiate NEC from other neonatal diseases that present with abdominal signs. Intestinal fatty acid binding protein (I-FABP) has been reported to be a useful plasma marker for early enterocyte cell death.5,6 The small (14–15 kDa) cytosolic I-FABP is specifically present in mature enterocytes of small and large intestine and is released as soon as cell membrane integrity is compromised. I-FABP is present in very small amounts in the plasma of healthy individuals, probably representing the normal turnover of enterocytes, but levels …


Journal of Pediatric Gastroenterology and Nutrition | 2015

Faecal Calprotectin in Suspected Paediatric Inflammatory Bowel Disease

Pieter L. J. Degraeuwe; Monique P A Beld; Merja Ashorn; Roberto Berni Canani; Andrew S. Day; Antonella Diamanti; Ulrika L. Fagerberg; Paul Henderson; Kaija-Leena Kolho; Els Van de Vijver; Patrick F. van Rheenen; David C. Wilson; Alfons G. H. Kessels

Objectives: The diagnostic accuracy of faecal calprotectin (FC) concentration for paediatric inflammatory bowel disease (IBD) is well described at the population level, but not at the individual level. We reassessed the diagnostic accuracy of FC in children with suspected IBD and developed an individual risk prediction rule using individual patient data. Methods: MEDLINE, EMBASE, DARE, and MEDION databases were searched to identify cohort studies evaluating the diagnostic performance of FC in paediatric patients suspected of having IBD. A standard study-level meta-analysis was performed. In an individual patient data meta-analysis, we reanalysed the diagnostic accuracy on a merged patient dataset. Using logistic regression analysis we investigated whether and how the FC value and patient characteristics influence the diagnostic precision. A prediction rule was derived for use in clinical practice and implemented in a spreadsheet calculator. Results: According to the study-level meta-analysis (9 studies, describing 853 patients), FC has a high overall sensitivity of 0.97 (95% confidence interval [CI] 0.92–0.99) and a specificity of 0.70 (0.59–0.79) for diagnosing IBD. In the patient-level pooled analysis of 742 patients from 8 diagnostic accuracy studies, we calculated that at an FC cutoff level of 50 &mgr;g/g there would be 17% (95% CI 15–20) false-positive and 2% (1–3) false-negative results. The final logistic regression model was based on individual data of 545 patients and included both FC level and age. The area under the receiver operating characteristic curve of this derived prediction model was 0.92 (95% CI 0.89–0.94). Conclusions: In high-prevalence circumstances, FC can be used as a noninvasive biomarker of paediatric IBD with only a small risk of missing cases. To quantify the individual patients’ risk, we developed a simple prediction model based on FC concentration and age. Although the derived prediction rule cannot substitute the clinical diagnostic process, it can help in selecting patients for endoscopic evaluation.


Therapeutic Drug Monitoring | 2006

Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.

Joyce Pullen; Lindsay de Rozario; Leo M. L. Stolk; Pieter L. J. Degraeuwe; Frank H. van Tiel; Luc J. I. Zimmermann

In total 235 flucloxacillin total (free+protein bound) plasma concentrations were determined in 55 neonates (gestational age 26 to 42 weeks, postnatal age 0 to 44 days) with reversed-phase HPLC in surplus plasma samples from routine gentamicin assays. Population pharmacokinetic parameters were calculated according to an one compartment open model with iterative two-stage Bayesian fitting (MWPHARM 3.50, Mediware, The Netherlands). Mean clearance corrected for weight was 0.18±0.10 L kg−1h−1 and volume of distribution corrected for weight was 0.54±0.17 L/kg. Pearson correlations between the individual pharmacokinetic parameters and covariates, like gestational age, plasma creatinine, and gentamicin clearance, were low and therefore not relevant for use in clinical practice. Total plasma concentrations above 200 mg/L were considered toxic and T>MIC (time above minimum inhibitory free plasma concentration) of more than 40% was considered effective. Protein binding was assumed to be 86.3% in all neonates, based on literature. The current dosage regimen, 25 or 50 mg/kg every 8 or 12 hours, did not result in effective plasma concentrations for the treatment of Staphylococcus aureus in 17 (31%) of the 55 neonates. Therefore, the authors suggest an initial dose of 25 mg/kg/4 h for all neonates, irrespective of their age, based on the breakpoint MIC value of flucloxacillin for Staphylococcus aureus (2.0 mg/L). After isolation of the causative agent of infection, flucloxacillin administration ought to be reconsidered based on the expected susceptibility pattern of the isolate. When oxacillin sensitive coagulase negative staphylococci are isolated, the initial dose should be reduced to 10 mg/kg/6 h, based on the breakpoint MIC value of 0.25 mg/L. Simulation with these new dosage regimens indicated that satisfactory plasma concentrations were reached in 52 of the 55 neonates. However, the regimens need prospective verification. Moreover, the exact role of neonatal protein binding needs to be further investigated.


Pediatric Pulmonology | 2000

Effect of perfluorochemical liquid ventilation on cardiac output and blood pressure variability in neonatal piglets with respiratory insufficiency

Pieter L. J. Degraeuwe; Gijs D. Vos; Gijs G. Geskens; Jan M. Geilen; Carlos E Blanco

Respiration and mechanical ventilation induce cyclic variation in cardiac output and blood pressure. We examined these phasic hemodynamic influences of mechanical ventilation during gas ventilation and partial and tidal liquid ventilation in 7 anesthetized and paralyzed young piglets (body weight, 3.0–4.9 kg) made respiratory‐insufficient by repeated saline lung lavage. Nonlinear regression analysis of cardiovascular parameters vs. time was done to quantify respiratory‐induced fluctuations in hemodynamic variables. The amplitude of oscillations was expressed as a percentage of the mean hemodynamic variable during the study period, and was called the relative oscillation amplitude.


Therapeutic Drug Monitoring | 2007

Protein binding of flucloxacillin in neonates.

Joyce Pullen; Leo M. L. Stolk; Pieter L. J. Degraeuwe; Frank H. van Tiel; Cees Neef; Luc J. I. Zimmermann

The isoxazolyl penicillins, including flucloxacillin, have the highest levels of plasma protein binding among the semisynthetic penicillins. Because only the free fraction of the penicillin is pharmacologically active, it would be useful to measure both protein-bound and free flucloxacillin to determine its protein binding. Until now, flucloxacillin protein binding in newborn infants has been investigated in only two studies with relatively small populations. In the present study, flucloxacillin protein binding was investigated in 56 (preterm) infants aged 3 to 87 days (gestational age, 25-41 weeks). Surplus plasma samples from routine gentamicin assays of each infant were collected and combined to obtain a sufficiently large sample for analysis. Free flucloxacillin was separated from protein-bound flucloxacillin using ultrafiltration. Reversed-phase high-performance liquid chromatography with ultraviolet detection was used to measure free flucloxacillin concentrations in ultrafiltrate and total flucloxacillin concentrations in pooled plasma. Flucloxacillin protein binding was 74.5% ± 13.1% (mean ± standard deviation) with a high variability among the infants (34.3% to 89.7%). High Pearson correlations were found between protein binding and the covariates-plasma albumin concentration (r = 0.804, P < 0.001, n = 18) and plasma creatinine concentration (r = −0.601, P < 0.001, n = 45). Statistically significant but less striking correlations were found between protein binding and gestational age, postconceptional age, body weight, and triglyceride concentration. Because of the high variability of protein binding among infants, it is difficult to devise a flucloxacillin dosage regimen effective for all infants. Individualized dosing, based on free flucloxacillin concentrations, might help to optimize treatment of late-onset neonatal sepsis, but practical obstacles will probably prevent analysis of free flucloxacillin concentrations in newborn infants on a routine basis.


Pediatric Pulmonology | 2008

Pleural effusion due to intra-abdominal extravasation of parenteral nutrition†

Jasper V. Been; Pieter L. J. Degraeuwe

An 8‐week‐old preterm boy experienced respiratory deterioration due to unilateral pleural effusion. Intra‐abdominal extravasation of parenteral fluid with leakage into the pleural cavity was suspected based on biochemical analysis of the effluent. Perforation of the central venous catheter in the peritoneal cavity was subsequently confirmed by contrast roentgenography. As in peritoneal dialysis and hepatic hydrothorax, pleuroperitoneal communication needs to be considered in patients exhibiting pleural effusion with a central venous line below the diaphragm. Pediatr Pulmonol. 2008; 43:1033–1035.


Systematic Reviews | 2014

A failed attempt to conduct an individual patient data meta-analysis.

Gerald J Jaspers; Pieter L. J. Degraeuwe

A study-level meta-analysis has shown that proton magnetic resonance spectroscopy is a promising prognostic marker in neonatal hypoxic-ischemic encephalopathy. An individual patient data meta-analysis could yield a prognostic tool with improved accuracy enabling well-founded clinical decisions. Our request to share patient data remained unanswered by five out of 18 research groups. Another four declined collaboration for various reasons, including own reanalysis of the data, and lack of parental consent. With less than 40% of the individual patient data available, we refrained from pursuing the proposed study. As future patients may benefit from it, policies mandating data sharing should be introduced.


Therapeutic Drug Monitoring | 2006

Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.

Joyce Pullen; Leo M. L. Stolk; Pieter L. J. Degraeuwe; Frank H. van Tiel; Cees Neef; Luc J. I. Zimmermann

Few reports have addressed neonatal rifampicin plasma concentrations and data on neonatal rifampicin pharmacokinetics are completely lacking. Therefore, plasma concentrations of rifampicin and its main metabolite 25-O-desacetylrifampicin (DES) were measured in 123 surplus plasma samples from routine vancomycin monitoring in 21 neonates using reversed-phase HPLC. Rifampicin peak and trough plasma concentrations were 4.66 ± 1.47 mg/L and 0.21 ± 0.20 mg/L, respectively, after a dose of 8.5 ± 2.1 (mean ± SD) mg/kg per day. A significant linear relationship between rifampicin dose and peak plasma concentrations was found, but inter-patient variability was high. Pharmacokinetic parameters of rifampicin were calculated according to a one-compartment open model with iterative two-stage Bayesian fitting (MW\PHARM 3.60, Mediware, The Netherlands). First-order elimination constant, volume of distribution corrected for weight, total body clearance corrected for weight (CL/W), and elimination half-life were 0.16 ± 0.06 h−1, 1.84 ± 0.59 L/kg, 0.28 ± 0.11 Lkg−1h−1, and 4.9 ± 1.7 h, respectively. A high Pearson correlation was found between CL/W rifampicin and the covariates plasma creatinine and CL/W gentamicin of a preceding gentamicin treatment course, r = 0.728 (n = 17) and r = 0.837 (n = 12), respectively. DES was detected in each plasma sample. Therefore, rifampicin seems to be eliminated by both renal and metabolic pathways in neonates. In 8 study patients, plasma concentrations of rifampicin and DES were measured again after two weeks of therapy. CL/W rifampicin was significantly higher (67 ± 50%). The authors suggest maintaining the current dose regimen of 10 mg/kg once a day. Because of the large inter-patient variability in rifampicin plasma concentrations and CL/W increase during therapy, the authors suggest monitoring rifampicin peak and trough plasma concentrations to avoid low plasma concentrations. More research is needed to determine well-founded dosing guidelines.


Neonatology | 1999

High-Frequency Oscillatory Ventilation, Partial Liquid Ventilation, or Conventional Mechanical Ventilation in NewbornPiglets with Saline Lavage-Induced Acute Lung Injury

Pieter L. J. Degraeuwe; Frederik B.J.M. Thunnissen; Gijs D. Vos; Carlos E Blanco

It has been reported that, in diseased lungs, either partial liquid ventilation (PLV) or high-frequency oscillatory ventilation (HFOV) can improve oxygenation better and with less lung injury than conventional mechanical ventilation (CMV). This study was intended as a preclinical comparison between the effects of HFOV, PLV and CMV on gas exchange, lung mechanics and histology. Fifteen anesthetized newborn piglets, with respiratory insufficiency due to repeated saline lung lavage, were allocated to either a PLV, HFOV or CMV (n = 5 each) strategy, and treated for 4 h. Within 30 min of commencing therapy, PLV, HFOV, and CMV improved arterial Po2 (Pa,o2), alveoloarterial oxygen gradient (P(A-a),o2), oxygenation index (OI), venous admixture (va), and arterial Pco2 (Pa,co2). After 4 h, oxygenation parameters (Pa,o2, P(A-a),o2, OI and venous admixture) were significantly better in the HFOV group than in the PLV group; the CMV group showed a higher Pa,o2 and lower OI than the PLV group. Gas exchange at the end of the experiment was not different from baseline in the HFOV and CMV groups. Lung histology and morphometry were performed after perfusion-fixation at endotracheal deflation pressure corresponding to mean airway pressure at the end of the experiment. Lung injury score and mean linear intercept were not different between the three treatment groups. We conclude that in this model, gas exchange improved significantly in all three ventilation strategies. Indices of oxygenation improved less during PLV. The saline lavage-induced acute lung injury model used as in this study, is less stable than previously thought. The final lung injury is not influenced by the ventilation strategy. We speculate that the impaired gas exchange during PLV is an expression of diffusion limitation and ventilation-perfusion mismatch in a recovering lung.

Collaboration


Dive into the Pieter L. J. Degraeuwe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cees Neef

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erik Heineman

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Gerald J Jaspers

Maastricht University Medical Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge